These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27783199)

  • 1. Compilation and physicochemical classification analysis of a diverse hERG inhibition database.
    Didziapetris R; Lanevskij K
    J Comput Aided Mol Des; 2016 Dec; 30(12):1175-1188. PubMed ID: 27783199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
    Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Support vector machines classification of hERG liabilities based on atom types.
    Jia L; Sun H
    Bioorg Med Chem; 2008 Jun; 16(11):6252-60. PubMed ID: 18448342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why are most phospholipidosis inducers also hERG blockers?
    Slavov S; Stoyanova-Slavova I; Li S; Zhao J; Huang R; Xia M; Beger R
    Arch Toxicol; 2017 Dec; 91(12):3885-3895. PubMed ID: 28551711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of hERG potassium channel blockage using ensemble learning methods and molecular fingerprints.
    Liu M; Zhang L; Li S; Yang T; Liu L; Zhao J; Liu H
    Toxicol Lett; 2020 Oct; 332():88-96. PubMed ID: 32629073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
    Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
    J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical QSAR analysis of hERG inhibition revisited: towards a quantitative potency prediction.
    Lanevskij K; Didziapetris R; Sazonovas A
    J Comput Aided Mol Des; 2022 Dec; 36(12):837-849. PubMed ID: 36305984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
    Moorthy NS; Ramos MJ; Fernandes PA
    SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers.
    Thai KM; Ecker GF
    Mol Divers; 2009 Aug; 13(3):321-36. PubMed ID: 19219559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.
    Yu HB; Zou BY; Wang XL; Li M
    Acta Pharmacol Sin; 2016 Jan; 37(1):111-23. PubMed ID: 26725739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine-learning technique, QSAR and molecular dynamics for hERG-drug interactions.
    Das NR; Sharma T; Toropov AA; Toropova AP; Tripathi MK; Achary PGR
    J Biomol Struct Dyn; 2023; 41(23):13766-13791. PubMed ID: 37021352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A QSAR model of HERG binding using a large, diverse, and internally consistent training set.
    Seierstad M; Agrafiotis DK
    Chem Biol Drug Des; 2006 Apr; 67(4):284-96. PubMed ID: 16629826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monte Carlo method for predicting of cardiac toxicity: hERG blocker compounds.
    Gobbi M; Beeg M; Toropova MA; Toropov AA; Salmona M
    Toxicol Lett; 2016 May; 250-251():42-6. PubMed ID: 27067105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryo-EM Structure of K
    Asai T; Adachi N; Moriya T; Oki H; Maru T; Kawasaki M; Suzuki K; Chen S; Ishii R; Yonemori K; Igaki S; Yasuda S; Ogasawara S; Senda T; Murata T
    Structure; 2021 Mar; 29(3):203-212.e4. PubMed ID: 33450182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the K
    van Veldhoven JPD; Campostrini G; van Gessel CJE; Ward-van Oostwaard D; Liu R; Mummery CL; Bellin M; IJzerman AP
    Eur J Med Chem; 2021 Feb; 212():113033. PubMed ID: 33261899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of an integrated database for hERG blocking small molecules.
    Sato T; Yuki H; Ogura K; Honma T
    PLoS One; 2018; 13(7):e0199348. PubMed ID: 29979714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pred-hERG: A Novel web-Accessible Computational Tool for Predicting Cardiac Toxicity.
    Braga RC; Alves VM; Silva MF; Muratov E; Fourches D; Lião LM; Tropsha A; Andrade CH
    Mol Inform; 2015 Oct; 34(10):698-701. PubMed ID: 27490970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.
    Shamovsky I; Connolly S; David L; Ivanova S; Nordén B; Springthorpe B; Urbahns K
    J Med Chem; 2008 Mar; 51(5):1162-78. PubMed ID: 18257512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative assessment of hERG liability as a function of lipophilicity.
    Waring MJ; Johnstone C
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1759-64. PubMed ID: 17239590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.